Platforms have been accused of putting consumers at risk by permitting highly complex products on their panels. But isn't suitability down to the adviser?
There has never been such a variety of unusual – and complex – products for advisers to research and recommend to their clients. Short, or inverse, ETFs – which effectively bet on the fall of an index or other benchmark – are a prime example. Last week, it emerged that five of the six most popular products on Ascentric were short ETFs – more often used by hedge fund managers than IFAs. But, with access to higher risk products on platforms, where would the blame lie should an adviser’s product recommendation go badly wrong? Difference of opinion Head of proposition at Skandia, ...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes